A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Active, not recruiting · Phase 2 · NCT06101134
Conditions: Melanoma
At a glance
- Research payments reported, 2025
- $122,889
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- relatlimab+nivolumab (drug), relatlimab+nivolumab+rHuPH20 (drug), nivolumab (drug), nivolumab+rHuPH20 (drug)
- Dates
- Started 2023-11-06; completion 2026-12-21
- Results posted
- Yes
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.
From ClinicalTrials.gov, last updated 2026-09-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $122,889 in research payments for this study in 2025 (6 payments).
Products named: Sotyktu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mahesh Seetharam, MD, FACP Hematology & Oncology · Phoenix, AZ
- Adil Daud, MD Medical Oncology · Tampa, FL
- Daniel B. Flora, M.D. Hematology & Oncology · Edgewood, KY
- Moises Harari Turquie, M.D Hematology & Oncology · Albuquerque, NM
- Jorge A. Garcia-zuazaga, M.D. Mohs Surgery · Concord Township, OH
- Stephen K. Tyring, MD PHD Dermatology · Webster, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Apex Clinical Research Center Llc $45,598
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $29,812
- New Mexico Cancer Research Alliance $25,453
- St Elizabeth Edgewood, KY $15,568
- Center for Clinical Studies $6,208
- Mayo Clinic $250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.